ANIX

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended April 30, 1995, for CopyTele, Inc. (Note: The request metadata listed "Anixa Biosciences Inc," but the filing text explicitly identifies the registrant as CopyTele, Inc.). The company is classified as a Development Stage Enterprise incorporated on November 5, 1982. It has generated no revenues since inception. Its primary activity involves a joint venture formed on March 28, 1995, with Shanghai Electronic Components Corp. to develop and market multi-functional telecommunication products in China.

Key Financial Metrics

Debt and Liquidity: The company has no long-term debt listed on the balance sheet. Current liabilities consist of accounts payable ($274,539) and accrued liabilities ($33,825). The company maintains a strong cash position, primarily invested in short-term, highly liquid instruments.

Material Changes vs. Prior Period

• Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased to $1,479,329 for the six months ended April 30, 1995, compared to $2,038,156 in the prior year period. This reduction is attributed to lower engineering supply expenditures and decreased patent application fees.
• Interest Income Increase: Interest income rose to $148,742 (six months) from $99,880 in the prior year, driven by higher interest rates on investment funds.
• Net Loss Improvement: The net loss narrowed to $1,330,587 for the six-month period, compared to $1,938,276 in the prior year.
• Joint Venture Formation: A material strategic change occurred with the March 28, 1995, formation of a joint venture in China, requiring an initial capital contribution of approximately $1.2 million.

Guidance, Outlook, and Risks

• Outlook: Management believes current funds are sufficient to maintain development efforts and make initial joint venture contributions through the first quarter of fiscal 1997. However, additional funding will likely be required to continue R&D and participate further in the joint venture.
• Revenue Uncertainty: There is no assurance that marketable telecommunications products will be developed or that the company will generate future revenues. The joint venture products face risks of obsolescence.
• Liquidity Risks: The company must maintain a minimum of $4 million in net tangible assets to comply with NASDAQ-NMS listing requirements. Management anticipates seeking additional funding to satisfy this requirement.
• Contingencies: The company's funding capacity assumes the continued waiver of salaries and pension benefits by the Chairman, President, and senior personnel. If these waivers cease, the runway for operations would shorten.
• Stock Option Plan: On May 3, 1995, options for 1,585,000 shares were granted pending shareholder approval to increase the plan limit. If not approved, these grants will be void.

Investor Verification Checklist

• Company Identity: Verify that the filing pertains to CopyTele, Inc., not Anixa Biosciences Inc.
• Revenue Generation: Confirm the company has zero revenue since inception (1982) and relies entirely on interest income and capital raises.
• Joint Venture Viability: Assess the risks associated with the new Chinese joint venture and the timeline for product commercialization.
• Listing Compliance: Monitor the company's ability to maintain the $4 million net tangible asset threshold required by NASDAQ.
• Executive Compensation: Note that key executives are currently waiving salaries; verify if this practice continues in future periods.
• Cash Burn Rate: Review the operating cash burn of approximately $1.2 million for the six-month period against the $6.9 million cash balance.